Telehealth company Hims & Hers Health (NYSE: HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its non-GAAP loss of $0.19 per share was significantly below analysts’ consensus estimates.

Is now the time to buy HIMS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritize branded medications over compounded products. CEO Andrew Dudum highlighted that this shift resulted in near-term financial pressures, including restructuring charges and margin compression, as the company adapted to evolving consumer demand and regulatory developments. The company also experienced increased investment in technology and operations, while its international business, led by acquired brands like ZAVA and Livewell, posted strong growth.

Looking forward, Hims & Hers Health’s guidance reflects expectations for accelerated growth driven by expanded specialty offerings, technology investments, and the pending acquisition of Eucalyptus. CFO Yemi Okupe emphasized that the company’s outlook incorporates ongoing margin headwinds as newer categories such as weight loss, labs, and international markets scale up. Management is also focused on leveraging artificial intelligence to enhance customer engagement and retention, with Dudum noting, “We plan to integrate AI throughout the customer journey to deliver a more personalized and proactive care experience.”

Key Insights from Management’s Remarks

Management attributed the quarter's performance to the weight loss segment's transition, a broadened specialty portfolio, and increased investment in technology infrastructure, while highlighting ongoing international expansion.

• Weight loss strategy shift: The company moved from advertising compounded GLP-1 weight loss products to prioritizing branded medications like the Wegovy pill and pen, resulting in short-term financial disruption but expanding the addressable market and driving higher customer engagement.
• Technology and AI investment: Hims & Hers invested in its AI team and infrastructure, launching products such as Labs AI and an AI weight loss companion, which are designed to support both customers and providers throughout the care journey and improve care quality and efficiency.
• International expansion progress: The acquisition of ZAVA and Livewell fueled strong international revenue growth, and the planned acquisition of Eucalyptus is set to expand the company’s footprint across Australia, the U.K., Germany, Japan, and Canada.
• New specialty launches: Growth in newer specialties like testosterone, menopause, and labs demonstrated the platform’s ability to expand its offerings and deepen long-term customer relationships through proactive health management.
• Margin pressures from strategic pivot: The shift to branded products and shorter shipping cadences in the weight loss segment led to gross margin compression and restructuring charges, with management indicating that margin volatility may persist as the company invests in scale and technology.

Drivers of Future Performance

Hims & Hers Health’s outlook is shaped by the expansion of weight loss and specialty categories, continued investment in technology, and the scaling of international operations.

• Growth in specialty categories: Management expects accelerated revenue from the expansion of weight loss, labs, and hormone specialties, with weight loss serving as a primary customer acquisition channel and cross-sell opportunity for other services on the platform.
• Margin headwinds and investment: CFO Yemi Okupe signaled continued gross margin compression as the company prioritizes scaling lower-margin specialties and invests heavily in technology and operational infrastructure, which are expected to drive efficiencies and higher margins in the mid-to-long term.
• International scaling and integration: The company anticipates that the closing and integration of Eucalyptus will open new international markets, enabling the replication of its U.S. playbook and adding further growth, though initial profitability may be tempered by upfront investment and operational ramp-up.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the adoption trajectory of branded weight loss products and the impact on customer engagement, (2) gross margin trends as the company continues to invest in technology and expand into new specialties, and (3) the integration progress and financial impact of the Eucalyptus acquisition. The pace of AI-driven product innovation and success in cross-selling additional specialties will also be important markers for execution.

Hims & Hers Health currently trades at $25.08, down from $29.42 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.